Publication detail

Breast cancer-specific mutations in CK1 epsilon inhibit Wnt/beta-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration

Foldynova-Trantirkova, S. Sekyrova, P. Tmejova, K. Brumovska, E. Bernatik, O. Blankenfeldt, W. Krejci, P. Kozubik, A. Dolezal, T. Trantirek, L. Bryja, V.

Original Title

Breast cancer-specific mutations in CK1 epsilon inhibit Wnt/beta-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration

Type

journal article in Web of Science

Language

English

Original Abstract

Introduction: Breast cancer is one of the most common types of cancer in women. One of the genes that were found mutated in breast cancer is casein kinase 1 epsilon (CK1 epsilon). Because CK1 epsilon is a crucial regulator of the Wnt signaling cascades, we determined how these CK1 epsilon mutations interfere with the Wnt pathway and affect the behavior of epithelial breast cancer cell lines. Methods: We performed in silico modeling of various mutations and analyzed the kinase activity of the CK1 epsilon mutants both in vitro and in vivo. Furthermore, we used reporter and small GTPase assays to identify how mutation of CK1 epsilon affects different branches of the Wnt signaling pathway. Based on these results, we employed cell adhesion and cell migration assays in MCF7 cells to demonstrate a crucial role for CK1 epsilon in these processes. Results: In silico modeling and in vivo data showed that autophosphorylation at Thr 44, a site adjacent to the breast cancer point mutations in the N-terminal lobe of human CK1 epsilon, is involved in positive regulation of the CK1 epsilon activity. Our data further demonstrate that, in mammalian cells, mutated forms of CK1 epsilon failed to affect the intracellular localization and phosphorylation of Dvl2; we were able to demonstrate that CK1 epsilon mutants were unable to enhance Dvl-induced TCF/LEF-mediated transcription, that CK1 epsilon mutants acted as loss-of-function in the Wnt/beta-catenin pathway, and that CK1 epsilon mutants activated the noncanonical Wnt/Rac-1 and NFAT pathways, similar to pharmacological inhibitors of CK1. In line with these findings, inhibition of CK1 promoted cell migration as well as decreased cell adhesion and E-cadherin expression in the breast cancer-derived cell line MCF7. Conclusions: In summary, these data suggest that the mutations of CK1 epsilon found in breast cancer can suppress Wnt/beta-catenin as well as promote the Wnt/Rac-1/JNK and Wnt/NFAT pathways, thus contributing to breast cancer development via effects on cell adhesion and migration. In terms of molecular mechanism, our data indicate that the breast cancer point mutations in the N-terminal lobe of CK1 epsilon, which are correlated with decreased phosphorylation activities of mutated forms of CK1 epsilon both in vitro and in vivo, interfere with positive autophosphorylation at Thr 44.

Keywords

KINASE-I-EPSILONBETA-CATENINEPITHELIAL-CELLSDISHEVELLED PHOSPHORYLATIONREGULATES GASTRULATIONSIGNALING PATHWAYTUMOR PROGRESSIONUP-REGULATIONWNT PATHWAYE-CADHERIN

Authors

Foldynova-Trantirkova, S.; Sekyrova, P.; Tmejova, K.; Brumovska, E.; Bernatik, O.; Blankenfeldt, W.; Krejci, P.; Kozubik, A.; Dolezal, T. ; Trantirek, L.; Bryja, V.

Released

27. 5. 2010

ISBN

1465-542X

Periodical

BREAST CANCER RESEARCH

Year of study

12

Number

3

State

United Kingdom of Great Britain and Northern Ireland

Pages from

1

Pages to

14

Pages count

14

URL

BibTex

@article{BUT183284,
  author="Foldynova-Trantirkova, S. and Sekyrova, P. and Tmejova, K. and Brumovska, E. and Bernatik, O. and Blankenfeldt, W. and Krejci, P. and Kozubik, A. and Dolezal, T. and Trantirek, L. and Bryja, V.",
  title="Breast cancer-specific mutations in CK1 epsilon inhibit Wnt/beta-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration",
  journal="BREAST CANCER RESEARCH",
  year="2010",
  volume="12",
  number="3",
  pages="1--14",
  doi="10.1186/bcr2581",
  issn="1465-542X",
  url="https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2581"
}